Cochlear Limited provides implantable hearing solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers cochlear implants, including Nucleus 7 and Kanso sound processors; Carina middle-ear implants and accessories; and Baha bone conduction implants, such as Baha attract system, Baha connect system, Baha softband, Baha 5 sound processor, Baha 5 power, Baha 5 superpower, other sound processors, and wireless accessories.
Read More…
Industry, Sector and Symbol
Industry Medical Devices
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+61-2-94286555
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.43 billion
Profitability
Miscellaneous
Employees3,500
Next Earnings DateN/A
OptionableOptionable
Cochlear (ASX:COH) Frequently Asked Questions
What is Cochlear's stock symbol?
Cochlear trades on the ASX under the ticker symbol "COH."
How often does Cochlear pay dividends? What is the dividend yield for Cochlear?
Cochlear announced a Final dividend on Tuesday, August 20th. Investors of record on Monday, October 14th will be paid a dividend of 1.75 per share on Monday, October 14th. This represents a dividend yield of 0.8%. The ex-dividend date of this dividend is Thursday, September 19th. View Cochlear's Dividend History.
What price target have analysts set for COH?
3 analysts have issued twelve-month price objectives for Cochlear's shares. Their forecasts range from A$53.00 to A$53.00. On average, they anticipate Cochlear's share price to reach A$53.00 in the next twelve months. This suggests that the stock has a possible downside of 75.0%. View Analyst Price Targets for Cochlear.
What is the consensus analysts' recommendation for Cochlear?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cochlear in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cochlear.
Has Cochlear been receiving favorable news coverage?
Headlines about COH stock have been trending somewhat positive this week, according to InfoTrie. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cochlear earned a coverage optimism score of 0.9 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Cochlear.
Who are some of Cochlear's key competitors?
Some companies that are related to Cochlear include Fisher & Paykel Healthcare (FPH), ConvaTec Group (CTEC), Inspire Medical Systems (INSP), Avita Medical (AVH), Stratec (SBS), Draegerwerk AG & Co KGaA (DRW3), Creo Medical Group (CREO), Medica Group (MGP), Hamilton Thorne (HTL), Impedimed (IPD), Cyclopharm (CYC), Titan Medical (TMD), Advanced Oncotherapy (AVO), Kromek Group (KMK) and REVA Medical (RVA).
What other stocks do shareholders of Cochlear own?
Who are Cochlear's key executives?
Cochlear's management team includes the folowing people:
- Mr. Diggory William Howitt, CEO, MD, Pres & Exec. Director (Age 52)
- Mr. Brent Andrew Cubis, Chief Financial Officer
- Mr. Jan Janssen, Chief Technology Officer
- Mr. Richard Brook, Pres of EMEA & Latin American Region
- Mr. Anthony Manna, Pres of Americas Region
What is Cochlear's stock price today?
One share of COH stock can currently be purchased for approximately A$211.68.
How big of a company is Cochlear?
What is Cochlear's official website?
How can I contact Cochlear?
Cochlear's mailing address is 1 University Avenue Macquarie University, SYDNEY, NSW 2109, Australia. The company can be reached via phone at +61-2-94286555.
MarketBeat Community Rating for Cochlear (ASX COH)
MarketBeat's community ratings are surveys of what our community members think about Cochlear and other stocks. Vote "Outperform" if you believe COH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe COH will underperform the S&P 500 over the long term. You may vote once every thirty days.
